| 24008 |
Ublituximab |
Briumvi® |
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. |
Rapid Review Complete |
2nd April 2024 |
 |
| - |
Ulipristal acetate |
Esmya® |
For the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
Rapid review complete |
1st June 2016 |
|
| - |
Ulipristal acetate |
Esmya® |
For the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
Rapid review complete |
22nd October 2013 |
|
| - |
Umeclidinium/vilanterol |
Anoro® |
As a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. |
Rapid review complete |
10th July 2014 |
|
| 21039 |
Upadacitinib |
Rinvoq® |
For active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy. |
Rapid review complete |
11th October 2021 |
|
| 21029 |
Upadacitinib |
Rinvoq® |
For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older, who are candidates for systemic therapy. |
Rapid review complete |
29th July 2021 |
|
| 21040 |
Upadacitinib |
Rinvoq® |
For adults with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. |
Rapid review complete |
19th October 2021 |
|
| 19047 |
Upadacitinib |
Rinvoq® |
For the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate. |
Rapid review complete |
10th December 2019 |
|
| 22047 |
Upadacitinib |
Rinvoq® |
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
Rapid review complete |
27th January 2023 |
|
| 23013 |
Upadacitinib |
Rinvoq® |
Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
Rapid Review Complete |
26th February 2024 |
|
| - |
Urea |
GlucoRx Allpresan® Diabetic Foam Cream |
For the treatment of dry and sensitive foot skin (Basic) and very dry to chapped foot skin (Intensive) in patients with Diabetes Mellitus. |
Rapid review complete |
25th July 2018 |
|
| - |
Ustekinumab |
Stelara® |
For the treatment of moderate to severe psoriasis. |
Assessment process complete |
8th December 2009 |
|
| - |
Ustekinumab |
Stelara® |
For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies |
Rapid review complete |
11th January 2017 |
|
| 19048 |
Ustekinumab |
Stelara® |
For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. |
Rapid review complete |
17th December 2019 |
|
